Operational sustainability is challenged by a persistent negative free cash flow trajectory, with quarterly outflows frequently exceeding $1 million while being partially obscured by $1 million in stock-based compensation.
| Metric | Mar'26 | Mar'25 | Mar'24 | Mar'23 | Mar'22 | Mar'21 | Mar'20 | Mar'19 | Mar'18 | Mar'17 | Mar'16 | Mar'15 | Mar'14 | Mar'13 | Mar'12 | Mar'11 | Mar'10 | Mar'09 | Mar'08 | Mar'07 | Mar'06 |
|---|
| Cash from Operations | -5.94M | -4.79M | -5.2M | -7.05M | -7.46M | -10.8M | -8.68M | -3.33M | -1.93M | -1.39M | -157.7K | -2.58M | -1.74M | 178.2K | -5.02M | -2.63M | -2.96M | -8.11M | -8.57M | -1.56M | -95.21K |
| Operating CF Margin % | -501.1% | -377.26% | -386.54% | -773.55% | -1879.6% | -1202.67% | -213.09% | -65.09% | -88.06% | -239.69% | -2.48% | -33.64% | -76.64% | 2.22% | -119.58% | -64.67% | -16.51% | -22.96% | -391.64% | 203.73% | -45.21% |
| Operating CF Growth % | -23.94% | 7.77% | 26.22% | 5.56% | 30.91% | -24.47% | -160.57% | -72.44% | -38.82% | -782.09% | 93.9% | -48.31% | -1077.59% | 103.55% | -90.62% | 10.85% | 63.57% | 5.31% | -449.8% | -1537% | - |
| Net Income | -6.55M | -7.12M | -13M | -11.51M | -15.02M | -8.81M | -7.32M | -4.1M | -1.79M | -1.85M | -2.83M | -4.68M | -3.04M | -2.27M | -7.89M | -21.01M | -4.81M | -521.58K | -5.21M | 1.52M | 91.9K |
| Depreciation & Amortization | 382K | 618K | 637K | 657K | 651K | 478K | 144K | 59K | 19.41K | 396.35K | 728.74K | 781.55K | 712.31K | 673.92K | 996.4K | 785.07K | 385.8K | 873.02K | 4.36M | 29.23K | 0 |
| Stock-Based Compensation | 452K | 1.64M | 1.77M | 2.84M | 2.2M | 658K | 770K | 610K | 576.25K | 203.2K | 214.25K | 833.13K | 181.03K | 824.81K | -23.27K | 130.4K | 130.4K | 450.85K | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | -451K | 0 | 0 | 0 | 0 | 15.61K | 18.97K | 579 | 5.16K | 698K | -365.12K | 172.83K | 4.1M | -3.28M | 221.04K | -744K | -117.65K | -25K |
| Other Non-Cash Items | -549K | 140K | 3.5M | 616K | 2.17M | 169K | 782K | -282K | -1.51K | -166.98K | 662.7K | 757.7K | 270.52K | 784.2K | 1.16M | 13.36M | 6.44M | 931.11K | -2.12M | -3.1M | -203.02K |
| Working Capital Changes | 320K | -72K | 1.89M | 794K | 2.54M | -3.29M | -3.06M | 380K | -754.58K | 10.25K | 1.07M | -277.82K | -561.34K | 527.8K | 565.75K | 3.97K | -1.82M | -10.07M | -4.85M | 110.64K | 40.91K |
| Change in Receivables | -2K | -8K | -25K | 5K | 50K | -42K | -49K | 474K | -33.77K | -144.71K | 80.46K | 146.99K | 374.96K | 468.31K | 587.12K | -6.82K | -4.52M | -2.73M | 808.98M | 0 | 0 |
| Change in Inventory | 36K | 180K | 1.01M | 897K | 1.93M | -1.23M | -4M | 239K | -424.71K | -14.56K | 545.29K | 646.66K | -204.64K | -26.7K | 5.56K | 30.23K | 1.76M | -1M | 342K | 0 | 0 |
| Change in Payables | 373K | 106K | 243K | -451K | 504K | -287K | 442K | -140K | -12.54K | 191.04K | -28.53K | -122.01K | -453.58K | 285.46K | -856.7K | -1.5M | 1.51M | -1.03M | -818.05M | 0 | 0 |
| Cash from Investing | -192K | -442K | -317K | -235K | -742K | 3.39M | -9.55M | -260K | -657.11K | -241.35K | -183.42K | -518.09K | 3.08K | -74.7K | 4.67M | -44.7K | -2M | 2.89M | 57.26M | -274.23K | -65.62M |
| Capital Expenditures | -709K | -112K | -138K | -619K | -236K | -1.59M | -4.39M | -60K | -200.56K | -145.68K | -122.19K | -76.53K | -8.48K | -326.08K | -5.48K | -285.44K | -1.2M | -2.49M | -17K | 0 | 0 |
| CapEx % of Revenue | 59.78% | 8.81% | 10.26% | 67.95% | 59.45% | 177.28% | 107.78% | 1.17% | 9.15% | 25.1% | 1.92% | 1% | 0.37% | 4.06% | 0.13% | 7.01% | 6.7% | 7.06% | 0.78% | - | - |
| Acquisitions | -21K | 0 | 0 | 538K | 0 | 122K | 0 | 0 | 0 | 0 | 16.41K | 165.91K | 0 | -207.34K | 2.68M | 0 | 0 | 220.89K | -6.25B | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 588K | -330K | -179K | 538K | -506K | -75K | -77K | -200K | -456.56K | -95.68K | -1.35K | -607.47K | 11.57K | -79.95K | 1.78M | 299.98K | -103.19K | 63.64K | 6.24B | -2.92M | -172.57K |
| Cash from Financing | 5.93M | 4.45M | 3.52M | 100K | 4.14M | 14.69M | -59K | 27.6M | 3.71M | 707.56K | 1.01M | 2.9M | 1.74M | 414.34K | -625.76K | 3.41M | 4.18M | -155.63K | -41.38M | 3M | 65.72M |
| Debt Issued (Net) | 620K | -3K | -3K | -3K | -3K | 530K | 0 | -1.88M | 35K | 202.69K | -732.74K | -61.31K | 0 | 414.34K | -625.76K | -429.07K | 1.37M | -453.33K | -4.34M | 3M | 870K |
| Equity Issued (Net) | 5.32M | 4.45M | 3.53M | 103K | 4.14M | 14.16M | -59K | 29.46M | 3.49M | 642.16K | 1.74M | 2.96M | 0 | 0 | 0 | 3.91M | 1.83M | 297.7K | -33.14M | 0 | 68.87M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -59K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -33.14M | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18K | 190.91K | -137.29K | 0 | 0 | 1.74M | -386.65K | 0 | -66.68K | 973.56K | 0 | -3.89M | 0 | -4.02M |
| Net Change in Cash | -198K | -793K | -2M | -7.26M | -4.09M | 7.29M | -18.35M | 23.95M | 1.12M | -952.66K | 666.2K | -202.07K | -37.86K | 501.47K | -1.02M | 740.36K | -1.01M | -6.27M | 7.23M | 1.17M | 65.72M |
| Free Cash Flow | -6.11M | -5.28M | -5.71M | -7.67M | -8.23M | -12.39M | -13.14M | -3.39M | -2.13M | -1.54M | -279.89K | -2.66M | -1.75M | -147.88K | -5.03M | -2.92M | -4.15M | -10.61M | -8.59M | -1.56M | -95.21K |
| FCF Margin % | -514.92% | -415.18% | -424.83% | -841.49% | -2073.8% | -1379.96% | -322.77% | -66.26% | -97.2% | -264.79% | -4.4% | -34.64% | -77.01% | -1.84% | -119.71% | -71.68% | -23.21% | -30.02% | -392.41% | 203.73% | -45.21% |
| FCF Growth % | -15.73% | 7.65% | 25.46% | 6.89% | 33.56% | 5.71% | -287.7% | -59.03% | -38.71% | -449.06% | 89.48% | -51.96% | -1083.76% | 97.06% | -72.18% | 29.71% | 60.83% | -23.54% | -450.89% | -1537% | - |
| FCF per Share | -0.06 | -0.07 | -0.10 | -0.15 | -0.16 | -0.30 | -0.33 | -0.10 | -0.08 | -0.06 | -0.02 | -0.18 | -0.21 | -0.02 | -1.73 | -1.93 | -3.60 | -10.51 | -10.02 | -1.12 | -0.30 |
| FCF Conversion (FCF/Net Income) | 0.91x | 0.67x | 0.40x | 0.61x | 0.50x | 1.23x | 1.19x | 0.81x | 1.08x | 0.75x | 0.06x | 0.56x | 0.58x | -0.08x | 0.65x | 0.13x | 0.62x | 15.54x | 1.64x | -1.03x | 0.21x |
| Interest Paid | 1K | 0 | 0 | 0 | 0 | 0 | 8K | 0 | 0 | 119.69K | 0 | 0 | 0 | 0 | 0 | 0 | 378.97K | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.43K | 0 | 0 | 0 | 0 | 0 | 0 | 12.94K | 0 | 0 | 0 | 0 |
Imminent liquidity and dilution
As reported in quarterly financial filings, IGC's operating cash flow consistently trails net income, with the OCF/NI ratio fluctuating between 0.18 and 1.68, suggesting that accounting losses do not fully capture the underlying cash requirements of the company's ongoing clinical development and research activities.
The persistent gap between net income and operating cash flow indicates that non-cash items and working capital swings are masking the true intensity of the company's cash burn. Investors should interpret this volatility as a sign that the firm's operational cash needs are highly sensitive to the timing of clinical trial milestones rather than predictable revenue generation.
Based on the provided cash flow data, IGC has maintained a consistently negative free cash flow trajectory, with quarterly outflows frequently exceeding $1 million, which highlights the company's total dependence on external financing to sustain its current clinical-stage research and development pipeline.
The negative FCF margins, which reached as low as -11.1% in 2026Q2, demonstrate that the company is not currently structured to generate self-sustaining cash flow. This trajectory suggests that without a fundamental shift in the business model, the company will continue to rely on dilutive equity issuance to fund its operations.
According to recent SEC filings, IGC's capital expenditure remains negligible, with quarterly spending often falling below $30,000, reflecting a business model that is currently focused on intangible clinical assets rather than the acquisition or maintenance of heavy physical manufacturing infrastructure.
The low capital intensity relative to revenue suggests that the company is not currently investing in proprietary production capacity, which may be a strategic choice to preserve cash. However, this lack of investment may also imply that the company is not yet preparing for the commercial-scale manufacturing required for its drug candidates.
As evidenced by the provided financial statements, IGC frequently utilizes stock-based compensation, with quarterly figures reaching as high as $1 million, which serves to artificially inflate operating cash flow metrics while simultaneously diluting the equity value for existing shareholders over the long term.
The reliance on stock-based compensation as a primary tool for managing cash outflows warrants further investigation, as it suggests that the company is prioritizing cash preservation at the expense of shareholder dilution. This practice may obscure the true cost of talent acquisition and retention in a highly competitive biotech environment.
Quick answers to the most common questions about buying IGC stock.
IGC Pharma, Inc. (IGC) generated $-5.9M in net cash from operating activities in 2026. This reflects the cash generated directly from core business operations.
IGC Pharma, Inc. (IGC) reported negative free cash flow of $6.1M in 2026, indicating capital requirements exceeded cash from operations.
IGC Pharma, Inc. (IGC) spent $0.7M on capital expenditures in 2026. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.